Per the Terms, independent licensed medical professionals are responsible for the medical care they provide, including whether a prescription is appropriate
Common experiences include: Longer periods between meals without hunger Easier portion control Reduced food noise Better adherence to healthy eating habits This is often the stage where patients realize theyre eating less without feeling deprived
High alcohol intake Drinking too much can increase abdominal fat

The shortage-based legal exemption that underpinned widespread compounded semaglutide availability is no longer active for either 503A pharmacies or 503B outsourcing facilities Compounded GLP-1 programs operating today must navigate a legal framework that includes restrictions on compounding drugs that are commercially available drugs - meaning the compounding pharmacy's specific formulation, documentation, and prescriber individualization process matters for legal compliance The FDA still permits compounding under 503A for individual patient-specific prescriptions that involve a prescriber-documented "significant difference" from the commercially available product - but that requires specific clinical justification, not just a standard intake form Availability of specific compounded GLP-1 formulations may be affected by FDA enforcement actions, pharmacy-specific compliance status, and ongoing regulatory developments in this space None of this means compounded GLP-1 programs are operating illegally

Individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome (MEN 2) are typically advised to avoid GLP-1based treatments
To enroll, one of the following must apply: BMI 27 and an obesity-related comorbid condition BMI 30 with or without comorbid condition Obesity-related comorbid conditions include but are not limited to diabetes, prediabetes, hypertension, dyslipidemia, CAD, osteoarthritis, and obstructive sleep apnea